Status:
COMPLETED
Study to Evaluate Multiple Doses of ERB-041 in Healthy, Female Japanese Subjects
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Healthy
Eligibility:
FEMALE
20-45 years
Phase:
PHASE1
Brief Summary
The primary objective is evaluate the safety, tolerability, and pharmacokinetics of multiple doses of ERB-041, an investigational drug, in healthy, female Japanese subjects.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Healthy as determined by the investigator on the basis of medical history and screening evaluations.
Exclusion
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00434187
Start Date
August 1 2006
End Date
October 1 2006
Last Update
July 10 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kan-nondai, Tsukuba-shi, Ibaraki, Japan, 305-0856